Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years

BJU International

Volumn 99, Issue 4, 2007, Pages 753-757

  Sun, Leon ^a   Moul, Judd W ^a,b   Hotaling, James M ^a   Rampersaud, Edward ^a   Dahm, Phillipp ^a   Robertson, Cary ^a   Fitzsimons, Nicholas ^a   Albala, David ^a   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Age adjusted PSA levels; PSA velocity; Sensitivity; Specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; AGE FACTORS; AGED; COHORT STUDIES; EARLY DIAGNOSIS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 33947315643     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06682.x     Document Type: Article

References (13)

1. Schmid HP, Riesen W, Prikler L. Update on screening for prostate cancer with prostate-specific antigen. Crit Rev Oncol Hematol 2004; 50: 71-8
2. Chodak G. Conservative management of clinically-localized prostate cancer. Can J Oncol 1994; 4 (Suppl. 1): 20-3
3. Smith CV, Bauer JJ, Connelly RR et al. Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol 2000; 164: 1964-7
4. Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. BJU Int 2004; 93 (Suppl. 1): 10-5
5. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
6. Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
7. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
8. Moul J, Connely R, Barko V et al. Should healthy men between the age of 40-49 be screened for prostate cancer: a Department of Defense (DOD), Center for Prostate Disease Research (CPDR), and Army Physical Fitness Research Institute (APFRI) prospective study at the U.S. Army War College (USAWC). J Urol 2000; 163 (Suppl.): 90
9. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1163-7
10. Jacobsen SJ, Jacobson DJ, Girman CJ et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 1999; 162: 1301-6
11. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70
12. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444-9
13. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000; 55: 791-5